<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03795064</url>
  </required_header>
  <id_info>
    <org_study_id>268/2018</org_study_id>
    <nct_id>NCT03795064</nct_id>
  </id_info>
  <brief_title>Immediate Versus Early Endovenous Ablation In Venous Ulcer</brief_title>
  <official_title>Immediate Versus Early Endovenous Ablation In Venous Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oulu University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is conducted to assess the effects of immediately started foam sclerotherapy in&#xD;
      venous ulcer compared to early intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently EVRA study showed that early endovenous ablation (foam sclerotherapy and/or&#xD;
      endothermal ablation) is beneficial for venous ulcer healing. This randomized controlled&#xD;
      trial is conducted to assess the effects of immediate foam sclerotherapy in the first visit&#xD;
      to vascular outpatient clinic (immediate intervention). Patients in control group will&#xD;
      receive foam sclerotherapy at four weeks (early intervention). Endothermal ablation is&#xD;
      performed in early setting in both groups when truncal vein anatomy is suitable. The primary&#xD;
      outcome for this study is the reduction of venous ulcer area at four weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous ulcer area</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>Venous ulcer area measured from calibrated digital photograph.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to ulcer healing</measure>
    <time_frame>0 to 360 days</time_frame>
    <description>Complete re-epithelialisation of ulcer area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time of active venous ulcer</measure>
    <time_frame>0 to 360 days</time_frame>
    <description>Time from when ulcer was first time noticed to complete re-epithelialisation of ulcer area.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Venous Ulcer</condition>
  <arm_group>
    <arm_group_label>Immediate Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be treated with foam sclerotherapy immediately in the first visit to outpatient clinic (immediate intervention).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will be treated with foam sclerotherapy in the following visit to outpatient clinic at four weeks (early intervention).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Foam sclerotherapy</intervention_name>
    <description>Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.</description>
    <arm_group_label>Early Intervention</arm_group_label>
    <arm_group_label>Immediate Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endothermal ablation</intervention_name>
    <description>Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.</description>
    <arm_group_label>Early Intervention</arm_group_label>
    <arm_group_label>Immediate Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Venous ulcer &gt; 1 month&#xD;
&#xD;
          -  Ulcer area &gt; 1cm2&#xD;
&#xD;
          -  Palpable distal pulses / Ankle-brachial index &gt; 0,8 / Toe-brachial index &gt; 70mmhg (at&#xD;
             least one criteria must be met)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Leg ulcers other than venous etiology&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  General contraindications for foam sclerotherapy&#xD;
&#xD;
          -  Ulcers requiring operation theater revision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oulu University Hospital, Vascular Department</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oulu University Hospital</investigator_affiliation>
    <investigator_full_name>Toni Pihlaja</investigator_full_name>
    <investigator_title>Vascular Specialist</investigator_title>
  </responsible_party>
  <keyword>Venous Ulcer</keyword>
  <keyword>Venous Insufficiency of Leg</keyword>
  <keyword>Varicose Veins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

